Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.

J Infect · 2021 · PMC7764469 · PMID 33373651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

All of them 2 , 3 , 4 , 5 demonstrated the beneficial effect of sofosbuvir-daclatasvir on the outcomes of COVID-19 patients; however, most of the differences between sofosbuvir-daclatasvir and comparator in terms of these clinical outcomes, such as clinical recovery, length of hospital stays and mortality did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.